AdAlta Ltd. (FWB:JDA) Filings

AdAlta Ltd.

Filings

FilingDateTypeFiled with
EW-001 Orphan Drug Designation, pre-IND updateNov 16, 2026Operations updateASX
$1.4m additional RDTI refundNov 11, 2026ResultsASX
Letter to Shareholders, Notice of AGM & Proxy FormOct 29, 2026Meeting noticeASX
Change of AGM DateOct 27, 2026Meeting noticeASX
Quarterly Appendix 4C and Activities ReportOct 25, 2026Quarterly reportASX
RDTI receipt, Advanced Overseas FindingOct 18, 2026ResultsASX
RDTI receipt, Advanced Overseas FindingOct 18, 2026ResultsASX
EW-001 JDC milestone approvalsOct 4, 2026Other filingsASX
China Representative Office opensSep 30, 2026Operations updateASX
Date of AGM & Closing Date for Director NominationsSep 29, 2026Meeting noticeASX
US FDA grants EW-001 pre-IND meetingSep 22, 2026Operations updateASX
Oribiotech deal validates AdAlta manufacturing strategySep 17, 2026Operations updateASX
CAR-TCR Summit posterSep 14, 2026Operations updateASX
Bilingual BIOSeedin Investor PresentationSep 9, 2026Operations updateASX
BZDS1901 special access scheme launch in ChinaSep 1, 2026Operations updateASX
Appendix 4G and Corporate Governance StatementAug 21, 2026Other filingsASX
Annual Report to shareholdersAug 21, 2026Annual reportASX
Preliminary Final ReportAug 21, 2026ResultsASX
Investor presentationAug 12, 2026Other filingsASX
EW-001 IIT study overall survival updateAug 9, 2026Other filingsASX
2 year survival milestone for EW-001 patientAug 4, 2026Other filingsASX
Quarterly Appendix 4C and Activities ReportJul 28, 2026Quarterly reportASX
Oktopi AI collaboration for research efficiencyJul 1, 2026Operations updateASX
Second BZDS1901 milestone paidJun 30, 2026Other filingsASX
Regulatory advisors appointed for BZDS1901May 24, 2026Operations updateASX
$2.5m placementMay 4, 2026FinancingASX
BZDS1901 manufacturing agreementApr 28, 2026Other filingsASX
Automated cell therapy manufacturing MoUApr 20, 2026Operations updateASX
BZDS1901 clinical updateMar 31, 2026Other filingsASX
AdCella and SHcell hold first JDC meetingMar 26, 2026Operations updateASX
New AD-214 patent grantedMar 19, 2026Other filingsASX
AdCella expands clinical advisory boardMar 3, 2026Other filingsASX
AdCella Clinical Advisory Board convenedFeb 25, 2026Other filingsASX
Half Yearly Report and AccountsFeb 19, 2026Interim reportASX
Quarterly Appendix 4C and Activities ReportJan 29, 2026Quarterly reportASX
AdCella milestones and regulatory progressJan 20, 2026Operations updateASX
Placement raises A$1.2 millionJan 12, 2026FinancingASX
CAR-T collaboration agreementJan 1, 2026Operations updateASX
$0.78 million FY25 RDTI refund receivedDec 3, 2025ResultsASX
AGM share consolidation resolution withdrawalNov 6, 2025Meeting outcomeASX
Meurs Group Investment Agreement UpdateOct 27, 2025FinancingASX
NLSC investment balance repaidOct 23, 2025FinancingASX
Letter to Shareholders, Notice of AGM & Proxy FormOct 23, 2025Meeting noticeASX
At market Placement raises additional up to A$1.1 millionOct 19, 2025FinancingASX
Placement raises up to A$0.5 million and transaction updateOct 12, 2025FinancingASX
Preliminary Final ReportAug 26, 2025ResultsASX
Investor Presentation - TechKnow Invest RoadshowAug 18, 2025Other filingsASX
Renounceable Rights Issue shortfall placedJun 12, 2025FinancingASX
Rights Issue raises $1.1millionJun 2, 2025FinancingASX
Notice of change of exercise price of optionsMay 28, 2025Other filingsASX
ProspectusMay 4, 2025Offer documentASX
Renounceable Rights Issue to Raise up to $1.3 millionMay 1, 2025FinancingASX
Trading HaltApr 29, 2025Trading halt or suspensionASX
SYNBV invest up to $2m in East to West subsidiaryMar 19, 2025FinancingASX
R&D Tax Incentive advance receivedMar 4, 2025Other filingsASX
Investor PresentationFeb 6, 2025Other filingsASX
East to West cell therapy strategy updateFeb 5, 2025Operations updateASX
AD-214 clinical advisory boardOct 9, 2024Other filingsASX
FY24 RDTI Refund Received $1.77mOct 3, 2024ResultsASX
Transaction, investment facility updateSep 2, 2024FinancingASX
$1.9 million raised from exercise of 1ADOA optionsJun 2, 2024FinancingASX
Cellular immunotherapy manufacturer secured - Cell TherapiesMay 12, 2024Operations updateASX
Extension of Victorian Government RDTI Loan FacilityApr 28, 2024FinancingASX
Institutional investment to pursue strategic initiativesApr 28, 2024FinancingASX
SYNBV MoU Webinar presentationApr 9, 2024Other filingsASX
SYNThesis BioVentures MoU for cellular immunotherapiesApr 7, 2024Operations updateASX
Corporate PresentationMar 7, 2024Other filingsASX
Positive AD-214 Phase I extension study resultsMar 5, 2024Other filingsASX
January 2024 partnering presentations and progressJan 21, 2024Other filingsASX
New malaria inhibiting i-bodyDec 18, 2023Other filingsASX
Chair address and CEO presentation to AGMNov 21, 2023Annual reportASX
AD-214 Phase I extension clinical study - interim resultsNov 20, 2023ResultsASX
Oversubscribed placement resultNov 6, 2023FinancingASX
Placement to raise up to $1.23millionNov 2, 2023FinancingASX
AD-214 well tolerated in Phase I extension studyOct 22, 2023Operations updateASX
R&D tax refund received & R&D Loan repayment terms extendedOct 17, 2023FinancingASX
Prof Foley invited presentation AD-214Sep 25, 2023Other filingsASX
Dosing simulations support AD-214 IV product profileSep 24, 2023Other filingsASX
AD-214 Phase I extension study fully enrolledSep 19, 2023Other filingsASX
AD-214 returns to clinicAug 3, 2023Other filingsASX
$1.87 million raised in oversubscribed Shortfall facilityJul 12, 2023Other filingsASX
New AD-214 data de-risks clinical studiesJul 6, 2023Other filingsASX
AD-214 clinical trial approvalJun 28, 2023Other filingsASX
Rights Offer resultsMay 24, 2023Other filingsASX
Rights Offer to fund early return to clinic and growthApr 27, 2023Other filingsASX
Publication highlights I-body potential in osteoporosisJan 24, 2023Other filingsASX
AdAlta welcomes new substantial shareholdersJan 23, 2023Other filingsASX
Second Japan patent for AD-214Jan 9, 2023Other filingsASX
AD-214 progress and priorities webinar presentationNov 1, 2022Other filingsASX
AD-214 progress and prioritiesNov 1, 2022Other filingsASX
Balance of R&D Tax Incentive Refund receivedOct 26, 2022Other filingsASX
1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancerOct 12, 2022Other filingsASX
R&D Tax Incentive Refund receivedOct 3, 2022Other filingsASX
AD-214 program update, cash runway extensionJul 3, 2022Other filingsASX
European Patent for AD-214 grantedJun 13, 2022Other filingsASX
BIO International Convention presentationMay 31, 2022Other filingsASX
AdAlta presentation at Bioshares Biotech SummitMay 9, 2022Other filingsASX
Indian patent for AD-214Apr 6, 2022Other filingsASX
Inhaled AD-214 preclinical programApr 4, 2022Other filingsASX
PAC Partners Healthcare Conference - Corporate PresentationApr 4, 2022Other filingsASX
$1.6M Second Tranche R&D Cash Flow Loan ReceivedMar 8, 2022Other filingsASX
Chinese patent granted for AD-214Mar 1, 2022Other filingsASX
Entitlement Offer ResultsFeb 3, 2022FinancingASX
Entitlement Offer BookletDec 22, 2021FinancingASX
Reinstatement to QuotationDec 14, 2021Trading halt or suspensionASX
Voluntary SuspensionDec 13, 2021Trading halt or suspensionASX
Inhaled AD-214 passes first development milestoneDec 8, 2021Other filingsASX
AGM presentations & first iCAR-T dataNov 28, 2021Other filingsASX
Second US patent for AD-214Nov 17, 2021Other filingsASX
BTB funding transferred to AD-214 inhalation programOct 6, 2021Other filingsASX
New pre-clinical data presented at Boston conferenceSep 26, 2021Other filingsASX
Corporate overview and IRD Invest 2021 presentationSep 20, 2021Other filingsASX
$4.0M Non-Dilutive Financing with Victorian GovernmentSep 19, 2021Other filingsASX
Carina collaboration webinar presentationAug 25, 2021Other filingsASX
CAR-T collaboration with Carina BiotechAug 23, 2021Other filingsASX
Webinar and presentation on AD-214 strategyJul 19, 2021Other filingsASX
AD-214 pathway to IPF efficacy studiesJul 18, 2021Other filingsASX
AdAlta secures AD-214 resupplyJul 1, 2021Other filingsASX
R&D Tax Incentive FacilityJun 24, 2021Other filingsASX
GE Healthcare collaboration advances to next stageMay 23, 2021Other filingsASX
AdAlta granted Japanese patent for AD-214May 18, 2021Other filingsASX
Mutiple Dose Part Of Ad-214 Phase I Trial CommencedApr 18, 2021Other filingsASX
Investor briefing-AD-214 top line single dose safety resultsMar 9, 2021Other filingsASX
Appendix 4D and Interim Financial ReportFeb 25, 2021Interim reportASX
FDA Orphan Drug Designation for AD-214Feb 23, 2021Other filingsASX
Phase I HV extension to explore encouraging resultsDec 13, 2020Other filingsASX
AGM PresentationNov 25, 2020Other filingsASX
AusBiotech presentation including Phase I status updateOct 26, 2020Other filingsASX
Investor Presentation - BIO investor forumOct 9, 2020Other filingsASX
GE Healthcare collaboration progressesSep 20, 2020Other filingsASX
Non-renounceable Rights Issue OfferAug 18, 2020FinancingASX
Placement and Rights OfferAug 10, 2020FinancingASX
Investor presentation including future milestonesJul 29, 2020Other filingsASX
First participants treated in AD-214 Phase I trialJul 23, 2020Other filingsASX
Supportive US FDA pre-IND meeting results for AD-214Jul 19, 2020Other filingsASX
AdAlta receives approval to commence AD-214 Phase I trialJun 9, 2020Other filingsASX
Business update and COVID-19 responseMar 30, 2020Operations updateASX
Board changes and R&D Tax Incentive advance receivedMar 26, 2020Other filingsASX
Investor Briefing - Strategic PlanMar 2, 2020Other filingsASX
AD-214 effective in gold standard pre-clinical animal modelMar 1, 2020Other filingsASX
Appendix 4C - quarterlyJan 30, 2020Quarterly reportASX
AdAlta Granted US Patent for AD-214Jan 29, 2020Other filingsASX
AD-214 Phase I strategy and timing updateJan 13, 2020Other filingsASX
AdAlta awarded Biomedical Translation Bridge FundingDec 12, 2019Other filingsASX
GLP Toxicology study resultsOct 28, 2019Other filingsASX
Tim Oldham Appointed as Chief Executive OfficerOct 8, 2019Other filingsASX
Receipt of R&D Tax IncentiveSep 17, 2019Other filingsASX
AdAlta secures licensing deal with GE HealthcareSep 15, 2019Other filingsASX
Executive team changesAug 11, 2019Other filingsASX
GLP toxicology study commencesJul 15, 2019Other filingsASX
Entitlement Offer Results and Shortfall NotificationJun 14, 2019FinancingASX
Completion of Capital Raise - $5 millionMay 23, 2019Other filingsASX
AD-214 manufacturing updateMay 2, 2019Other filingsASX
Manufacturing updateJan 28, 2019Other filingsASX
Appendix 4C - Quarter ended 30 September 2018Oct 16, 2018Quarterly reportASX
Manufacturing UpdateOct 14, 2018Other filingsASX
Change of Registry Address: Automic P/L - Sydney OfficeSep 28, 2018Other filingsASX
Investor presentation and conference callJul 31, 2018Other filingsASX
Appendix 4C - Quarter ended 30 June 2018Jul 15, 2018Quarterly reportASX
Completion of Capital Raise - $4.25m to advance AD-214Jul 12, 2018Other filingsASX
AdAlta secures key manufacturing agreements for AD-214Jun 4, 2018Other filingsASX
Appendix 4C - Quarter Ended 31 March 2018Apr 22, 2018Quarterly reportASX
AdAlta to advance improved lung fibrosis therapy, AD-214Apr 17, 2018Other filingsASX
AdAlta collaborator awarded NHMRC grantDec 6, 2017Other filingsASX
AdAlta granted key Australian PatentNov 16, 2017Other filingsASX
Commercial agreement with XL-proteinNov 13, 2017Other filingsASX
Conference PresentationOct 31, 2017Other filingsASX
Results of multi-dose toxicology studySep 18, 2017Other filingsASX
AdAlta awarded SIEF grantJul 23, 2017Other filingsASX
Toxicology study and manufacturing updateJul 17, 2017Other filingsASX
Presentation of Eye Fobrosis Data at ARVO MeetingMay 8, 2017Other filingsASX
AdAlta expands partnership with Alfred HospitalMar 20, 2017Other filingsASX
AdAlta receives Orphan Designation for AD-114Jan 18, 2017Other filingsASX
Positive Pre-clinical DataJan 8, 2017Other filingsASX
Commercialisation Agreement with Crossbeta BiosciencesNov 7, 2016Other filingsASX
Quarterly Review and Appendix 4COct 26, 2016Quarterly reportASX
Receipt of Innovation Connections GrantSep 13, 2016Other filingsASX
Agreement with FujiFilm Diosynth BiotechnologiesSep 12, 2016Other filingsASX